ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000884

An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay

Identifieur interne : 000884 ( PascalFrancis/Curation ); précédent : 000883; suivant : 000885

An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay

Auteurs : André Bonnici [Canada] ; Carola-Ellen Ruiner [Canada] ; Lyne St-Laurent [Canada] ; David Hornstein [Canada]

Source :

The Annals of pharmacotherapy [ 1060-0280 ] ; 2010.

RBID : Pascal:10-0439685

Descripteurs français

Pascal (Inist)
- Interaction, Lévodopa, Voie entérale, Syndrome malin, Prolongé, Maladie de Parkinson, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Enteral administration, Human, Interaction, Levodopa, Malignant syndrome, Parkinson disease, Prolonged.

Abstract

OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.

A01	`01`	`1`		`@0 1060-0280`
A02	`01`			`@0 APHRER`
A03		`1`		`@0 Ann. pharmacother.`
A05				`@2 44`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay`
A11	`01`	`1`		`@1 BONNICI (André)`
A11	`02`	`1`		`@1 RUINER (Carola-Ellen)`
A11	`03`	`1`		`@1 ST-LAURENT (Lyne)`
A11	`04`	`1`		`@1 HORNSTEIN (David)`
A14	`01`			`@1 McGill University Health Centre, Université de Montréal @2 Montreal, Quebec @3 CAN @Z 1 aut.`
A14	`02`			`@1 Faculty of Medicine, McGill University and McGill University Health Centre @3 CAN @Z 2 aut.`
A14	`03`			`@1 Department of Clinical Nutrition, McGill University Health Centre @3 CAN @Z 3 aut.`
A14	`04`			`@1 Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital @3 CAN @Z 4 aut.`
A20				`@1 1504-1507`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13925 @5 354000194257850180`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 10-0439685`
A60				`@1 P @3 EC`
A61				`@0 A`
A64	`01`	`1`		`@0 The Annals of pharmacotherapy`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.
C02	`01`	`X`		`@0 002B02`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Interaction @5 01`
C03	`01`	`X`	`ENG`	`@0 Interaction @5 01`
C03	`01`	`X`	`SPA`	`@0 Interacción @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 02`
C03	`02`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 02`
C03	`02`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 02`
C03	`03`	`X`	`FRE`	`@0 Voie entérale @5 03`
C03	`03`	`X`	`ENG`	`@0 Enteral administration @5 03`
C03	`03`	`X`	`SPA`	`@0 Vía enteral @5 03`
C03	`04`	`X`	`FRE`	`@0 Syndrome malin @5 04`
C03	`04`	`X`	`ENG`	`@0 Malignant syndrome @5 04`
C03	`04`	`X`	`SPA`	`@0 Síndrome maligno @5 04`
C03	`05`	`X`	`FRE`	`@0 Prolongé @5 05`
C03	`05`	`X`	`ENG`	`@0 Prolonged @5 05`
C03	`05`	`X`	`SPA`	`@0 Prolongado @5 05`
C03	`06`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 06`
C03	`06`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 06`
C03	`06`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 06`
C03	`07`	`X`	`FRE`	`@0 Homme @5 07`
C03	`07`	`X`	`ENG`	`@0 Human @5 07`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 07`
C07	`01`	`X`	`FRE`	`@0 Agoniste @5 37`
C07	`01`	`X`	`ENG`	`@0 Agonist @5 37`
C07	`01`	`X`	`SPA`	`@0 Agonista @5 37`
C07	`02`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 38`
C07	`02`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 38`
C07	`02`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 38`
C07	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 39`
C07	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 39`
C07	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`04`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 41`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 42`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 42`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 42`
C07	`07`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 43`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 43`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 43`
C07	`08`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 44`
C07	`08`	`X`	`ENG`	`@0 Central nervous system disease @5 44`
C07	`08`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 44`
N21				`@1 284`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000393

Links to Exploration step

Pascal:10-0439685

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay</title>
<author><name sortKey="Bonnici, Andre" sort="Bonnici, Andre" uniqKey="Bonnici A" first="André" last="Bonnici">André Bonnici</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McGill University Health Centre, Université de Montréal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Ruiner, Carola Ellen" sort="Ruiner, Carola Ellen" uniqKey="Ruiner C" first="Carola-Ellen" last="Ruiner">Carola-Ellen Ruiner</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Medicine, McGill University and McGill University Health Centre</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="St Laurent, Lyne" sort="St Laurent, Lyne" uniqKey="St Laurent L" first="Lyne" last="St-Laurent">Lyne St-Laurent</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Nutrition, McGill University Health Centre</s1>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Hornstein, David" sort="Hornstein, David" uniqKey="Hornstein D" first="David" last="Hornstein">David Hornstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</s1>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0439685</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0439685 INIST</idno>
<idno type="RBID">Pascal:10-0439685</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000393</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000884</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay</title>
<author><name sortKey="Bonnici, Andre" sort="Bonnici, Andre" uniqKey="Bonnici A" first="André" last="Bonnici">André Bonnici</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>McGill University Health Centre, Université de Montréal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Ruiner, Carola Ellen" sort="Ruiner, Carola Ellen" uniqKey="Ruiner C" first="Carola-Ellen" last="Ruiner">Carola-Ellen Ruiner</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Medicine, McGill University and McGill University Health Centre</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="St Laurent, Lyne" sort="St Laurent, Lyne" uniqKey="St Laurent L" first="Lyne" last="St-Laurent">Lyne St-Laurent</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Clinical Nutrition, McGill University Health Centre</s1>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Hornstein, David" sort="Hornstein, David" uniqKey="Hornstein D" first="David" last="Hornstein">David Hornstein</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</s1>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Annals of pharmacotherapy</title>
<title level="j" type="abbreviated">Ann. pharmacother.</title>
<idno type="ISSN">1060-0280</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Annals of pharmacotherapy</title>
<title level="j" type="abbreviated">Ann. pharmacother.</title>
<idno type="ISSN">1060-0280</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Enteral administration</term>
<term>Human</term>
<term>Interaction</term>
<term>Levodopa</term>
<term>Malignant syndrome</term>
<term>Parkinson disease</term>
<term>Prolonged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Interaction</term>
<term>Lévodopa</term>
<term>Voie entérale</term>
<term>Syndrome malin</term>
<term>Prolongé</term>
<term>Maladie de Parkinson</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1060-0280</s0>
</fA01>
<fA02 i1="01"><s0>APHRER</s0>
</fA02>
<fA03 i2="1"><s0>Ann. pharmacother.</s0>
</fA03>
<fA05><s2>44</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BONNICI (André)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RUINER (Carola-Ellen)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ST-LAURENT (Lyne)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HORNSTEIN (David)</s1>
</fA11>
<fA14 i1="01"><s1>McGill University Health Centre, Université de Montréal</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Faculty of Medicine, McGill University and McGill University Health Centre</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Clinical Nutrition, McGill University Health Centre</s1>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Medicine, Faculty of Medicine, McGill University; Internal Medicine and Critical Care, SMBD Jewish General Hospital, and McGill University Health Center, Montreal General Hospital</s1>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1504-1507</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13925</s2>
<s5>354000194257850180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0439685</s0>
</fA47>
<fA60><s1>P</s1>
<s3>EC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Annals of pharmacotherapy</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>OBJECTIVE: To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE SUMMARY: A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 °C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission. DISCUSSION: Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale. CONCLUSIONS: Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Interaction</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Interaction</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Interacción</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Voie entérale</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Enteral administration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vía enteral</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Syndrome malin</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Malignant syndrome</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Síndrome maligno</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Prolongé</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prolonged</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Prolongado</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>07</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Agonist</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Agonista</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>44</s5>
</fC07>
<fN21><s1>284</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000884 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000884 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0439685
   |texte=   An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay

An Interaction Between Levodopa and Enteral Nutrition Resulting in Neuroleptic Malignant-Like Syndrome and Prolonged ICU Stay

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri